An experimental simian immunodeficiency virus vaccine boosts production of memory T cells at the site where the virus first contacts the body—in the mucosa (pages 293–299). The approach has the potential to result in more effective HIV vaccines than those currently under development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hansen, S.E. et al. Nat. Med. 15, 293–299 (2009).
Daniel, M.D. Science 258, 1938–1941 (1992).
Baba, T.W. et al. Nat. Med. 5, 194–103 (1999).
Sallusto, F., Geginat, J. & Lanzavecchia, A. Annu. Rev. Immunol. 22, 745–763 (2004).
Pitcher, C.J. et al. J. Immunol. 168, 29–43 (2002).
Vaccari, M. et al. J. Immunol. 175, 3502–3507 (2005).
Cristillo A.D. et al. Virology 366, 197–211 (2007).
Van Rompay, K.K.A. et al. J. Acquir. Immune Defic. Syndr. 38, 124–134 (2005).
Fauci, A.S. Science 321, 530–532 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Franchini, G. Choosing the right memory T cell for HIV. Nat Med 15, 244–246 (2009). https://doi.org/10.1038/nm0309-244
Issue Date:
DOI: https://doi.org/10.1038/nm0309-244
